- 20 Feb 2018 Salmonellosis, st I 4,[5],12:b:- - USA: kratom
- 20 Feb 2018 Avian influenza (34): Sweden (BL) HPAI H5N6, new strain, OIE
- 20 Feb 2018 Influenza (08): Nepal (Kathmandu) post influenza cough, type B association susp.
- 20 Feb 2018 Norovirus - South Korea (04): (KW) Winter Olympics
- 20 Feb 2018 Avian influenza (33): South Africa, HPAI H5N8, penguin; Iraq, HPAI H5N8, poultry
- 20 Feb 2018 Pentobarbital, dog food - USA: recall
- 20 Feb 2018 Piscine reovirus - North America: USA, Canada, salmon
- 20 Feb 2018 Cannabinoid hyperemesis syndrome
- 20 Feb 2018 E. coli EHEC - Canada: cheese, 2013, 60 day rule
- 20 Feb 2018 Mumps update: USA
- 19 Feb 2018 Stem rust, wheat - UK: Digalu strain, 1st rep
- 19 Feb 2018 Lumpy skin disease - Europe: Balkans 2017, vaccination, control
- 19 Feb 2018 Hepatitis - India: (JK)
- 18 Feb 2018 Influenza D, equine - USA
- 18 Feb 2018 Hantavirus - Americas (12): Chile (AR, AI) Argentina (BA) Panama (LS)
- 18 Feb 2018 Undiagnosed deaths, bovine - India: (OR) RFI
- 18 Feb 2018 Listeriosis - South Africa (06): fatal, more cases
- 18 Feb 2018 Cholera, diarrhea & dysentery update (07): Asia (Yemen) WHO
- 18 Feb 2018 Salmonellosis, st Typhimurium - USA: (IA, MN) chicken salad, alert, recall
- 18 Feb 2018 Measles update (12): Africa, Europe, North America, Pacific
- 18 Feb 2018 Equine herpesvirus - North America (09): USA (AZ, ID, KY, NY)
- 17 Feb 2018 Yellow fever - Americas (14): PAHO/WHO
- 17 Feb 2018 Salmonellosis, st I 4,[5],12:b:- and Newport - USA (02): frozen coconut, recall
- 17 Feb 2018 Yellow fever - Americas (13): Brazil
- 17 Feb 2018 Brucellosis - Oman: (JA) caprine, ovine, bovine
- 17 Feb 2018 Norovirus - South Korea (03): (KW) Winter Olympics
- 16 Feb 2018 Cholera, diarrhea & dysentery update (06): Africa, Asia, Oceania
- 16 Feb 2018 Toxic coffee - Malaysia: (PP) methamphetamine
- 16 Feb 2018 Sporotrichosis - Australia: (WA)
- 16 Feb 2018 Avian influenza (32): Cambodia (PY) poultry, HPAI H5N1, spread
- 16 Feb 2018 Hepatitis A - USA (08): (WY)
- 16 Feb 2018 Psittacosis - China: (HK)
- 16 Feb 2018 Equine infectious anemia - Slovakia: (BC) OIE
- 15 Feb 2018 Lymphatic filariasis - Côte d'Ivoire
- 15 Feb 2018 Salmonella, pet food - USA: recall
- 15 Feb 2018 Rabies (08): Americas (USA) fox, susp., human exposure
- 15 Feb 2018 Anthrax - Papua New Guinea: (MD) porcine, susp
- 15 Feb 2018 Strangles, equine - USA: (MI)
- 15 Feb 2018 Equine herpesvirus, equine (02): EHV-8, poss. association with abortion in mares
- 15 Feb 2018 Coccidioidomycosis - Worldwide: outbreaks, epidemiology, 1940-2015
- 15 Feb 2018 Hepatitis A - USA (07): (CA, UT, MI)
- 15 Feb 2018 Tularemia - USA: (CA) infected ticks
- 15 Feb 2018 Ixodes ricinus tick - UK: expanding distribution
- 15 Feb 2018 Influenza (07): seasonal, H1N1, research
- 15 Feb 2018 Lassa fever - West Africa (11): Nigeria, WHO
- 15 Feb 2018 Avian influenza (31): Ghana (BA) poultry, HPAI H9N2, new strain, OIE
- 14 Feb 2018 Chronic wasting disease, cervid - USA (05): (PA, MS)
- 14 Feb 2018 Phytoplasma/liberibacter coinfection, citrus - Iran: (KE)
- 14 Feb 2018 Salmonellosis - USA (03): (IA) chicken salad, alert, recall
- 14 Feb 2018 Botulism - USA: (CA) wound, injection drug-related
- 14 Feb 2018 Scombroid fish poisoning - Australia: (QL) tuna, alert
- 14 Feb 2018 Hepatitis - Syria: (RD) students
- 14 Feb 2018 Campylobacteriosis - USA (03): (CO) raw milk, herdshare, 2016
- 14 Feb 2018 Legionellosis - USA (3): (IL) vet home, updated water treatment, new cases, RFI
- 14 Feb 2018 Avian influenza, human (07): China (JS) H7N4, 1st report
- 14 Feb 2018 Legionellosis - Australia: (NS)
- 14 Feb 2018 Cattle eye helminth, Thelazia gulosa, human - USA: (OR) 1st rep
- 14 Feb 2018 MERS-CoV (08): Saudi Arabia, RFI
- 14 Feb 2018 Measles update (11): Pacific, Europe, USA
- 14 Feb 2018 Brucellosis - Nigeria: (BA) butchers, serosurvey
- 13 Feb 2018 Hepatitis E - Namibia (04): (KH) fatal
- 13 Feb 2018 Avian influenza (30): China (Hong Kong) wild bird, HPAI H5N6, OIE
- 13 Feb 2018 Avian influenza (29): Ireland (TY) HPAI H5N6, new strain, OIE
- 13 Feb 2018 Hantavirus - Americas (11): USA, Canada
- 13 Feb 2018 Avian influenza, human (06): China (GD) H7N9
- 13 Feb 2018 Foot & mouth disease - Russia: (ZB) bovine, st O, OIE
- 12 Feb 2018 Foot & mouth disease - Nepal: (GA) livestock, st Asia 1, OIE
- 12 Feb 2018 Sudden decline, date palm - Pakistan: (SD)
- 12 Feb 2018 Bovine tuberculosis - Ireland (04): (KY) probable badger source
- 12 Feb 2018 Anthrax - Turkey: (Trabzon) bovine, human
- 12 Feb 2018 Lassa fever - West Africa (10): Nigeria
- 12 Feb 2018 Salmonellosis - USA (02): (CO) restaurant, fatal
- 12 Feb 2018 Microbiological laboratory mishaps - UK: 2015-2017
- 12 Feb 2018 Equine herpesvirus, equine: EHV-8, poss association with abortion in mares
- 11 Feb 2018 Undiagnosed diseases, maize & cassava - Uganda: (SX)
- 11 Feb 2018 Yellow fever - Americas (12): Brazil monkeys
- 11 Feb 2018 Equine herpesvirus - North America (08): USA (OH) equine
- 11 Feb 2018 Norovirus - Canada (Montreal) raspberries ex China
- 11 Feb 2018 Norovirus - South Korea (02): (KW) Winter Olympics
- 11 Feb 2018 Salmonellosis, st Reading - USA: (MN) children, raw pet food, alert, recall
- 11 Feb 2018 Chronic wasting disease, cervid - USA (04): (MS)
- 11 Feb 2018 Meningitis - Spain (03): listeriosis, raw soft ewe cheese, Portugal, recall, RFI
- 10 Feb 2018 Epizootic ulcerative syndrome, fish - UK: (England), 1st rep, OIE
- 10 Feb 2018 Measles update (10): Europe, Pacific, South America, USA
- 10 Feb 2018 Meningitis - Spain (02): (MD) foodborne, raw cheese, recall, comment
- 10 Feb 2018 Lassa fever - West Africa (09): Liberia ex Guinea
- 10 Feb 2018 Melioidosis - Australia (02): (NT)
- 10 Feb 2018 Schmallenberg virus - Europe (03): UK (N. Ireland), ovine
- 10 Feb 2018 Hepatitis A - Denmark: dates, alert, recall
- 10 Feb 2018 Avian influenza (28): Ireland (TY) HPAI H5N6, wild birds
- 09 Feb 2018 Lassa fever - West Africa (08): Liberia ex Guinea
- 09 Feb 2018 Hantavirus - Americas (10): Chile, (LI)
- 09 Feb 2018 Meningitis - Spain: (MD) foodborne, raw cheese, recall, alert, RFI
- 09 Feb 2018 Equine parvovirus-hepatitis, vaccine associated - USA
- 09 Feb 2018 Botulism, bovine - Australia: (NS)
- 09 Feb 2018 Chronic wasting disease, cervid - USA (03): (IA)
- 09 Feb 2018 Salmonellosis - Guatemala: (GU) bakery
- 09 Feb 2018 Equine herpesvirus - North America (07): USA (WA, VA, ID, WY, KY) equine
- 09 Feb 2018 Mycoplasma bovis, bovine - New Zealand (02)
- 09 Feb 2018 Paralytic shellfish poisoning - Chile
- 09 Feb 2018 Crimean-Congo hem. fever - Namibia: (OH)
- 09 Feb 2018 Legionellosis - USA (02): (TX) military medical center, staff, new case, RFI
- 09 Feb 2018 Dengue/DHF update (04): Asia, Pacific, vaccination, research
- 09 Feb 2018 Chikungunya (02): Kenya, Italy research
- 09 Feb 2018 Zika virus (04): Americas, research, observations
- 09 Feb 2018 Chlorine gas exposure - India: (WB)
- 09 Feb 2018 Norovirus - South Korea: (KW) Winter Olympics
- 08 Feb 2018 Asian greening, citrus - China
- 08 Feb 2018 Poliomyelitis update (07): (Pakistan, Afghanistan, Congo DR)
- 08 Feb 2018 Undiagnosed dieback, cocoa - Nigeria: southwest
- 08 Feb 2018 Hepatitis A - USA (06): (CA)
- 08 Feb 2018 Botulism - Brazil: (PE, SP)
- 08 Feb 2018 Glanders, equine - India (02): (GJ)
- 08 Feb 2018 Anthrax - Namibia: (Etosha Natl Park) wildlife, dust bathing risk
- 08 Feb 2018 Syphilis - USA: congenital, rising incidence
- 08 Feb 2018 Avian influenza (27): Israel, Taiwan HPAI H5N8, Afghanistan, HPAI H5, OIE, RFI
- 08 Feb 2018 Psittacosis - Argentina: (ER)
- 08 Feb 2018 Dengue/DHF update (03): Americas, research, observations
- 08 Feb 2018 Carbapenem-resistant organisms - New Zealand: (Auckland) nosocomial, burn center
- 08 Feb 2018 Yellow fever - Africa (03): Nigeria (BO) vaccination campaign
- 08 Feb 2018 Yellow fever - Americas (11): Brazil monkeys
- 08 Feb 2018 Influenza (06): WHO global update, universal vaccine
- 07 Feb 2018 Phytoplasma wilt, banana - Papua New Guinea: spread
- 07 Feb 2018 Tuberculosis, elephant - Zimbabwe: diagnosis, prevention and control strategies
- 07 Feb 2018 Encephalitis - India: (UP) AES due to scrub typhus
- 07 Feb 2018 HIV - India: (UP) wandering medical practitioner, shared needle, alert
- 07 Feb 2018 Varicella update (02): USA (NY) background
- 07 Feb 2018 Avian influenza (26): UK (England) HPAI H5N6, non-poultry birds, spread
- 07 Feb 2018 Legionellosis - USA: (MI) fatal, low chlorine levels, Flint city water, 2014-15
- 06 Feb 2018 Rift Valley fever - South Sudan (03): (EL)
- 06 Feb 2018 Kyasanur Forest disease - India (06): (MH) alert
- 06 Feb 2018 Lassa fever - West Africa (07): Nigeria
- 05 Feb 2018 Avian influenza (25): Iran (GI) HPAI H5N6, new strain, OIE
- 05 Feb 2018 Streptococcus group A, scarlet fever - UK: (England, Wales) increased cases
- 05 Feb 2018 New in IJID (02): February 2018
- 05 Feb 2018 Avian influenza, human (05): human-animal interface, WHO
- 05 Feb 2018 False smut, rice - India: (TN)
- 05 Feb 2018 Measles update (09): Europe, Caribbean, Central America
- 04 Feb 2018 Varicella update (01): USA (NY)
- 04 Feb 2018 Panleukopenia, feline - Australia: (VI)
- 04 Feb 2018 Koi herpesvirus disease - South Africa: (NL) OIE
- 04 Feb 2018 Avian influenza (24): UK (England) HPAI H5N6, wild birds
- 04 Feb 2018 Epizootic ulcerative syndrome, fish - South Africa: (Kruger Natl Park) OIE
- 03 Feb 2018 Bovine tuberculosis - Armenia: (ER), zoo, camelid, OIE
- 03 Feb 2018 Staph. aureus (MRSA) - Japan: human-to-horse transmission
- 03 Feb 2018 Rabies (09): Asia (Israel) wildlife, spread (India) human, treatment modified
- 03 Feb 2018 Foot & mouth disease - Zimbabwe: (MW, ME) bovine, serotype not typed, OIE
- 03 Feb 2018 Botulism - Canada (02): trout caviar, risk, further expanded recall
- 03 Feb 2018 Scabies - Spain (02): (CT)
- 03 Feb 2018 Tuberculosis, MDR - Nepal
- 03 Feb 2018 Campylobacteriosis - USA (02): canine, human, CDC advisory
- 03 Feb 2018 Vibrio vulnificus - Uruguay: fatal, alert
- 03 Feb 2018 Malaria - Southeast Asia: increasing artemisinin resistance
- 02 Feb 2018 Poliomyelitis update (06): Global (Afghanistan)
- 02 Feb 2018 Avian influenza (23): China (Hong Kong) poultry, HPAI H5N6, OIE
- 02 Feb 2018 Japanese encephalitis - Malaysia: (SK)
- 02 Feb 2018 Salmonellosis, st Agona - France (04): infant formula
- 02 Feb 2018 Melioidosis - Australia: (NT)
- 01 Feb 2018 Measles update (08): Asia, Central America, North America, Europe
- 01 Feb 2018 Hantavirus - Americas (09): USA, Canada
- 01 Feb 2018 Lassa fever - West Africa (06): Nigeria (DE, ON)
- 01 Feb 2018 Population decline, apis - USA: (FL)
- 01 Feb 2018 Zika virus (03): Americas, Asia, research, observations
- 01 Feb 2018 Hantavirus - Americas (08): Chile (LL) susp.
- 01 Feb 2018 Anthrax - Zimbabwe (02): 2016, OIE
- 01 Feb 2018 Legionellosis - Portugal: (Lisbon) nosocomial, RFI
- 01 Feb 2018 Cryptococcus neoformans - USA: (CA) meningitis, immunocompet., marijuana smoker
- 01 Feb 2018 Crimean-Congo hem. fever - East Africa (03): Uganda (NK)
- 01 Feb 2018 Mycoplasma bovine, bovine - New Zealand (02)
- 01 Feb 2018 Equine herpesvirus - North America (06): USA (PA,GA,OR) equine
- 01 Feb 2018 Botulism, avian - New Zealand: (WK/BP) waterfowl
- 31 Jan 2018 Avian influenza (22): South Korea (KG) HPAI H5N6, poultry, spread
- 31 Jan 2018 Pertussis (02): USA, Venezuela, New Zealand
- 31 Jan 2018 Lassa fever - West Africa (05): Nigeria
- 31 Jan 2018 Yellow fever - Americas (10): Brazil
- 31 Jan 2018 Poliomyelitis update (05): Afghanistan, RFI
- 31 Jan 2018 Listeriosis - South Africa (05): fatal, more cases
- 30 Jan 2018 Rift Valley fever - South Sudan (02): (EL)
- 30 Jan 2018 Hantavirus - Americas (07): Uruguay (CA) fatal, susp.
- 30 Jan 2018 Undiagnosed hemorrhagic illness - Cameroon: RFI
- 30 Jan 2018 Anthrax - Zimbabwe: human
- 30 Jan 2018 Hand, foot & mouth disease update (01): Japan, research
- 30 Jan 2018 Hantavirus - Americas (06): Panama (LS)
- 30 Jan 2018 Kyasanur Forest disease - India (05): (MH) new cases
- 29 Jan 2018 Liberibacter, carrot - Portugal: 1st rep
- 29 Jan 2018 Yellow fever - Americas (09): Brazil, monkeys
- 29 Jan 2018 Foot & mouth disease - China (02): (NX) st. O, livestock, OIE
- 29 Jan 2018 African swine fever - Europe (03): Ukraine, wild boar, domestic swine, OIE
- 29 Jan 2018 Hantavirus - Americas (05): Chile (LR)
- 29 Jan 2018 Avian influenza (21): Netherlands, wild bird, HPAI H5N6, OIE
- 29 Jan 2018 Avian cholera - USA: (IN) wild fowl
- 29 Jan 2018 Cholera, diarrhea & dysentery update (05): Asia (Yemen) WHO
- 28 Jan 2018 MERS-CoV (07): Saudi Arabia
- 28 Jan 2018 Hepatitis A - USA (05): (MI, UT, CA)
- 28 Jan 2018 Measles update (07): Africa, USA, Caribbean, Canada, Europe
- 28 Jan 2018 Salmonellosis, st Agona - France (03): infant formula
- 27 Jan 2018 Equine herpesvirus - North America (05): USA (NY) equine
- 27 Jan 2018 Rabies (08): Asia (Malaysia-SK) human, animal
- 27 Jan 2018 Mycoplasma bovine, bovine - New Zealand (03): correction
- 27 Jan 2018 Campylobacteriosis - USA: canine, human, CDC advisory
- 27 Jan 2018 Cholera, diarrhea & dysentery update (04): Africa
- 27 Jan 2018 Yellow fever - Americas (08): Brazil
- 27 Jan 2018 Diphtheria - Australia: (QL)
- 27 Jan 2018 Q fever - Chile
- 27 Jan 2018 Foodborne illness - Argentina: fatalities, pesticide susp.
- 27 Jan 2018 Avian influenza (20): Taiwan, poultry, HPAI H5N2, spread, OIE
- 27 Jan 2018 Hepatitis A - Spain: (PM) restaurant
- 27 Jan 2018 Typhoid fever - Pakistan (02): (SD) multidrug resistance, fatal
- 27 Jan 2018 Mycoplasma bovine, bovine - New Zealand (03)
- 27 Jan 2018 Hepatitis E - Namibia (03): (KH) fatal
- 26 Jan 2018 MERS-CoV (06): Saudi Arabia, WHO
- 26 Jan 2018 Avian influenza (19): Iran, HPAI H5N8 susp, poultry, spread, RFI
- 26 Jan 2018 Condor die-off - Argentina: poisoning susp.
- 26 Jan 2018 Equine herpesvirus - North America (04): (MD) equine
- 26 Jan 2018 Listeriosis - South Africa (04): comment
- 26 Jan 2018 Contagious bovine pleuropneumonia - Nigeria: (KT) spread
- 26 Jan 2018 Yellow fever - Americas (07): Brazil vaccination PAHO/WHO
- 26 Jan 2018 Newcastle disease - Colombia: (CU) avian, alert
- 26 Jan 2018 Dengue/DHF update (02): Asia, Pacific, vaccination, research
- 26 Jan 2018 Undiagnosed collapse, peanut - USA: (FL), RFI
- 25 Jan 2018 Lassa fever - West Africa (04): Nigeria
- 25 Jan 2018 Poliomyelitis update (04): global (Afghanistan, Pakistan), Nigeria rumors
- 25 Jan 2018 Glanders, equine - Indonesia: (JK), OIE
- 25 Jan 2018 Anthrax, human, livestock - Argentina: (BS) 2017
- 25 Jan 2018 Avian influenza (18): UK (England) HPAI H5N6, wild birds
- 25 Jan 2018 Yellow fever - Africa (02): Nigeria vaccination campaign
- 24 Jan 2018 Rift Valley fever - Gambia: (BJ) WHO
- 24 Jan 2018 Kyasanur Forest disease - India (04): (KL)
- 24 Jan 2018 Typhoid fever - Pakistan: (SD) multidrug resistance, fatal, RFI
- 24 Jan 2018 Rift Valley fever - Uganda
- 24 Jan 2018 Yellow fever - Americas (06): Brazil (SP)
- 24 Jan 2018 MERS-CoV (05): Saudi Arabia
- 24 Jan 2018 Lassa fever - West Africa (03): Benin (AK) ex Nigeria, WHO
- 24 Jan 2018 Bovine tuberculosis - Ireland (03): (KY) epidemiological notes
- 24 Jan 2018 Lassa fever - West Africa (02): Nigeria, Benin (AK) ex Nigeria
- 24 Jan 2018 Botulism - Nigeria: (Abuja) fish, fatal
- 24 Jan 2018 Yellow fever - Americas (05): Brazil, WHO
- 24 Jan 2018 Foodborne illness - China: (HB) sodium nitrate, children
- 24 Jan 2018 Equine herpesvirus - North America (03): USA (PA)
- 23 Jan 2018 Bluetongue - Europe: Italy (SC) ovine, st. 3, 2017, transb epidemiology
- 23 Jan 2018 Avian influenza (17): Afghanistan (KB), poultry HPAI H5, OIE
- 23 Jan 2018 Equine influenza, equine - Chile: serotype H3N8, OIE
- 23 Jan 2018 Measles update (06): Americas, Europe, Asia/Pacific
- 23 Jan 2018 Avian Influenza, human (04): Iraq (SD), NOT
- 22 Jan 2018 Listeriosis - South Africa (03): fatal, increasing incidence, ST6
- 22 Jan 2018 Bovine tuberculosis - Ireland (02): comment, RFI
- 22 Jan 2018 Avian influenza, human (03): Iraq (SD)
- 22 Jan 2018 Calendar (01): 2nd Int'l Conference on Zika Virus & Aedes Related Infections
- 22 Jan 2018 Old World screwworm - Singapore: (Singapore Zoo) sambar, 1st rep, OIE
- 22 Jan 2018 Hantavirus - Americas (04): Chile (LG), susp.
- 22 Jan 2018 Rabies (07): Americas (Costa Rica) bovine
- 22 Jan 2018 Plague - Madagascar: (AV) bubonic
- 21 Jan 2018 Bovine tuberculosis - Ireland: (KY) spread, control
- 21 Jan 2018 Bacterial leaf streak, maize - USA: reservoir hosts
- 21 Jan 2018 Influenza, canine - USA (02): (CA) H3N2
- 21 Jan 2018 Carbon dioxide poisoning - USA: (IL)
- 21 Jan 2018 Anthrax - Kenya: (NR) bovine, human
- 21 Jan 2018 Equine herpesvirus - North America (02): USA (PA, VA) equine
- 21 Jan 2018 Scabies - Spain: (CT)
- 21 Jan 2018 Guinea worm: Chad, Ethiopia, increase
- 21 Jan 2018 Influenza (05): seasonal, multiple locations
- 21 Jan 2018 Scrub typhus - Thailand (02): comment
- 21 Jan 2018 Salmonellosis, st Montevideo - USA: restaurant chain, sprouts
Published Date: 2018-02-20 21:27:21
Subject: PRO/AH/EDR> Salmonellosis, st I 4,[5],12:b:- - USA: kratom
Archive Number: 20180220.5640222
Subject: PRO/AH/EDR> Salmonellosis, st I 4,[5],12:b:- - USA: kratom
Archive Number: 20180220.5640222
SALMONELLOSIS, SEROTYPE I 4,[5],12:B:- - USA: KRATOM
****************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org
Date: Tue 20 Feb 2018, 10:30 AM ET
Source: CDC [edited]
https://www.cdc.gov/salmonella/kratom-02-18/index.html
Multistate Outbreak of _Salmonella_ I 4,[5],12:b:- Infections Linked to Kratom
--------------------------------------------------------------------------------
CDC, public health and regulatory officials in several states, and the FDA are investigating a multistate outbreak of _Salmonella [enterica_ serotype] I 4,[5],12:b:- infections.
Public health investigators are using the PulseNet system to identify illnesses that may be part of this outbreak. PulseNet is the national subtyping network of public health and food regulatory agency laboratories coordinated by CDC. DNA fingerprinting is performed on _Salmonella_ bacteria isolated from ill people by using techniques called pulsed-field gel electrophoresis (PFGE) and whole genome sequencing (WGS). CDC PulseNet manages a national database of these DNA fingerprints to identify possible outbreaks. WGS gives a more detailed DNA fingerprint than PFGE.
As of [16 Feb 2018], 28 people infected with the outbreak strain of _S._ I 4,[5],12:b:- have been reported from 20 states. A list of the states and the number of cases in each can be found on the Case Count Map page. WGS performed on isolates from ill people were closely related genetically. This means that people in this outbreak are more likely to share a common source of infection.
States / Case Count
Alabama / 1
Arizona / 1
California / 3
Colorado / 1
Florida / 1
Kansas / 1
Kentucky / 1
Louisiana / 1
Massachusetts / 1
Michigan / 1
North Carolina / 2
North Dakota / 1
New York / 1
Ohio / 2
Oklahoma / 2
Oregon / 2
Pennsylvania / 2
South Carolina / 1
Tennessee / 1
Utah / 2
Total / 28
Illnesses started on dates ranging from [13 Oct 2017] to [30 Jan 2018]. Ill people range in age from 6 to 67 years, with a median age of 41. 16 people are male. A total of 11 hospitalizations have been reported. No deaths have been reported.
WGS analysis did not identify any predicted antimicrobial resistance in isolates from 5 ill people. Testing of outbreak isolates using standard antimicrobial susceptibility testing methods is currently underway in CDC's National Antimicrobial Resistance Monitoring System (NARMS) laboratory.
Investigation of the Outbreak
-----------------------------
Epidemiologic evidence indicates that kratom is a likely source of this multistate outbreak. Kratom is a plant consumed for its stimulant effects and as an opioid substitute. Kratom is also known as Thang, Kakuam, Thom, Ketom, and Biak.
In interviews, ill people answered questions about the foods they ate and other exposures in the months before they became ill. As many as 8 (73 percent) of 11 people interviewed reported consuming kratom in pills, powder, or tea. No common brands or suppliers of kratom have been identified at this time.
At this time, CDC recommends that people not consume kratom in any form. The investigation indicates that kratom products could be contaminated with _Salmonella_ and could make people sick. CDC's recommendation may change as more information becomes available. This investigation is ongoing and we will provide updates as needed.
--
Communicated by:
ProMED-mail
<promed@promedmail.org>
[The following about kratom is from Drugs.com (https://www.drugs.com/illicit/kratom.html)
Kratom
------
[Author: L. Anderson, PharmD]
Common or Street Names: Thang, Krypton, Kakuam, Thom, Ketum, Biak-Biak (common name in Thailand)
"What is Kratom?
---------------
Kratom (_Mitragyna speciosa_) is a tropical evergreen tree from Southeast Asia and is native to Thailand, Malaysia, Indonesia and Papua New Guinea. Kratom, the original name used in Thailand, is a member of the Rubiaceae family. Other members of the Rubiaceae family include coffee and gardenia. The leaves of kratom are consumed either by chewing, or by drying and smoking, putting into capsules, tablets or extract, or by boiling into a tea. The effects are unique in that stimulation occurs at low doses and opioid-like depressant and euphoric effects occur at higher doses. Common uses include treatment of pain, to help prevent withdrawal from opiates (such as prescription narcotics or heroin), and for mild stimulation. Traditionally, kratom leaves have been used by Thai and Malaysian natives and workers for centuries. The stimulant effect was used by workers in Southeast Asia to increase energy, stamina, and limit fatigue. However, some Southeast Asian countries now outlaw its use.
In the USA, this herbal product has been used as an alternative agent for muscle pain relief, diarrhea, and as a treatment for opiate addiction and withdrawal. However, its safety and effectiveness for these conditions has not been clinically determined, and the FDA has raised serious concerns about toxicity and possible death with use of kratom. As published on 6 Feb 2018, the FDA notes it has no scientific data that would support the use of kratom for medical purposes. In addition, the FDA states that kratom should not be used as an alternative to prescription opioids, even if using it for opioid withdrawal symptoms. As noted by the FDA, effective, FDA-approved prescription medications, including buprenorphine, methadone, and naltrexone, are available from a health care provider, to be used in conjunction with counseling, for opioid withdrawal. Also, they state there are also safer, non-opioid options for the treatment of pain.
DEA Scheduling of Kratom
------------------------
Kratom was on the DEA's list of drugs and chemicals of concern for several years. On 31 Aug 2016, the DEA published a notice that it was planning to place kratom in Schedule I, the most restrictive classification of the Controlled Substances Act. Its 2 primary active ingredients, mitragynine and 7-hydroxymitragynine (7-HMG), would be temporarily placed onto Schedule I on 30 Sep 2016, according to a filing by the DEA. The DEA reasoning was "to avoid an imminent hazard to public safety. The DEA did not solicit public comments on this federal rule, as is normally done.
However, the scheduling of kratom did not occur on 30 Sep 2016. Dozens of members of Congress, as well as researchers and kratom advocates have expressed an outcry over the scheduling of kratom and the lack of public commenting. The DEA withheld scheduling at that time and opened the docket for public comments. Over 23 000 public comments were collected before the closing date of 1 Dec 2016, according to the American Kratom Association. The American Kratom Association is a lobbying and advocacy group in support of kratom use. The American Kratom Association reports that there are a "number of misconceptions, misunderstandings and lies floating around about Kratom."
As reported by the Washington Post in December 2016, Jack Henningfield, an addiction specialist from Johns Hopkins University and Vice President, Research, Health Policy, and Abuse Liability at Pinney Associates, was contracted by the American Kratom Association to research the kratom's effects. In Henningfield's 127 page report he suggested that kratom should be regulated as a natural supplement, such as St. Johns Wort or Valerian, under the FDA's Food, Drug and Cosmetic Act. The American Kratom Association then submitted this report to the DEA during the public comment period.
Next steps include review by the DEA of the public comments in the kratom docket, review of recommendations from the FDA on scheduling, and determination of additional analysis. Possible outcomes could include emergency scheduling and immediate placement of kratom into the most restrictive Schedule I; routine DEA scheduling in schedule 2 through 5 with more public commenting; or no scheduling at all. The timing for the determination of any of these events is unknown.
State laws have banned kratom use in several states including, Indiana, Tennessee, Wisconsin, Vermont, Arkansas, Alabama and the District of Columbia. These states classify kratom as a schedule I substance. Kratom is also noted as being banned in Sarasota County, Florida, San Diego County, California, and Denver, Colorado. The FDA's analysis from February 2018 included 44 reported deaths associated with the use of kratom. According to Governing.com, legislation was considered last year [2017] in at least 6 other states -- Florida, Kentucky, New Hampshire, New Jersey, New York and North Carolina.
What is the Pharmacology of Kratom?
-----------------------------------
As reported in February 2018, the FDA has confirmed from analysis that kratom has opioid properties. More than 20 alkaloids in kratom have been identified in the laboratory, including those responsible for the majority of the pain-relieving action, the indole alkaloid mitragynine, structurally related to yohimbine. Mitragynine is classified as a kappa-opioid receptor agonist and is roughly 13 times more potent than morphine. Mitragynine is thought to be responsible for the opioid-like effects.
Kratom, due to its opioid-like action, has been used for treatment of pain and opioid withdrawal. Animal studies suggest that the primary mitragynine pharmacologic action occurs at the mu and delta-opioid receptors, as well as serotonergic and noradrenergic pathways in the spinal cord. Stimulation at post-synaptic alpha-2 adrenergic receptors, and receptor blocking at 5-hydroxytryptamine 2A may also occur. The 7-hydroxymitragynine may have a higher affinity for the opioid receptors. Partial agonist activity may be involved. Additional animals' studies show that these opioid-receptor effects are reversible with the opioid antagonist naloxone.
Time to peak concentration in animal studies is reported to be 1.26 hours, and elimination half-life is 3.85 hours. Effects are dose-dependent and occur rapidly, reportedly beginning within 10 minutes after consumption and lasting from 1 to 5 hours.
Kratom Effects and Actions
--------------------------
Most of the psychoactive effects of kratom have evolved from anecdotal and case reports. Kratom has an unusual action of producing both stimulant effects at lower doses and more CNS depressant side effects at higher doses. Stimulant effects manifest as increased alertness, boosted physical energy, talkativeness, and a more social behavior. At higher doses, the opioid and CNS depressant effects predominate, but effects can be variable and unpredictable. Consumers who use kratom anecdotally report lessened anxiety and stress, lessened fatigue, pain relief, sharpened focus, relief of withdrawal symptoms,
Beside pain, other anecdotal uses include as an anti-inflammatory, antipyretic (to lower fever), antitussive (cough suppressant), antihypertensive (to lower blood pressure), as a local anesthetic, to lower blood sugar, and as an antidiarrheal. It has also been promoted to enhance sexual function. None of the uses have been studied clinically or are proven to be safe or effective. In addition, it has been reported that opioid-addicted individuals use kratom to help avoid narcotic-like withdrawal side effects when other opioids are not available. Kratom withdrawal side effects may include irritability, anxiety, craving, yawning, runny nose, stomach cramps, sweating and diarrhea; all similar to opioid withdrawal.
Deaths reported by the FDA have involved one person who had no historical or toxicologic evidence of opioid use, except for kratom. In addition, reports suggest kratom may be used in combination with other drugs that have action in the brain, including illicit drugs, prescription opioids, benzodiazepines and over-the-counter medications, like the anti-diarrheal medicine, loperamide (Imodium AD). Mixing kratom, other opioids, and other types of medication can be dangerous. Kratom has been shown to have opioid receptor activity, and mixing prescription opioids, or even over-the-counter medications such as loperamide, with kratom may lead to serious side effects.
Extent of Kratom Use
--------------------
On the Internet, kratom is marketed in a variety of forms: raw leaf, powder, gum, dried in capsules, pressed into tablets, and as a concentrated extract. In the US and Europe, it appears its use is expanding, and recent reports note increasing use by the college-aged population.
The DEA states that drug abuse surveys have not monitored kratom use or abuse in the US, so it's true demographic extent of use, abuse, addiction, or toxicity is not known. However, as reported by the DEA in 2016, there were 660 calls to U.S. poison centers related to kratom exposure from 2010 to 2015.
Kratom Side Effects and Health Hazards
--------------------------------------
Expected opioid-like side effects that may occur with kratom include:
- Sedation
- Nausea
- Sweating
- Dry mouth
- Increased urination
- Loss of appetite
- Itching
- Constipation
- Dizziness
- Confusion
Case reports describe the following adverse effects from kratom: addiction, withdrawal, hypothyroidism, and liver injury, aching of muscles and bones and jerky limb movements.
Kratom addiction and chronic use has led to cases of psychosis with hallucinations, delusion, and confusion. High-dose use may lead to fast heart rate (tachycardia) and low blood pressure (hypotension). Tremor, anorexia and weight loss are other possible side effects with long-term use.
Seizures have been reported when kratom was combined with modafinil in at least one case report. The DEA has also reported seizure adverse events with recreations kratom use.
A case series from Kronstad, et al. described a fatal drug interaction with kratom. A substance, dubbed "Krypton" - a mixture of mitragynine and a metabolite of tramadol - was found post-mortem in 9 people in Sweden over a one year period. Tramadol, an opioid-like prescription pain drug, was most likely added to kratom to boost its narcotic-like effect.
In November 2017 and February 2018, the FDA issued a public health advisory about deadly risks associated with kratom. There have been 44 reports of Kratom-related deaths, sometimes used in combination with other illicit drugs, prescription drugs, or over-the-counter agents such as loperamide (Imodium).
As with many herbal alternatives, designer drugs, or illicit products sold on the Internet, the possibility exists that kratom may also be contaminated with illegal drugs, black market prescription medications, or even poisonous products. Consumers should avoid buying unknown drug products from the Internet. When combined with other drugs -- recreational, prescription, or alcohol -- the effects of kratom are unknown and may be dangerous.
Is Kratom Addictive?
--------------------
Kratom is well-known to be addictive, as found with traditional use by natives over many years in Southeast Asian countries. Withdrawal effects similar to narcotic withdrawal and drug-seeking behaviors have been described in users in Southeast Asia. Many Southeast Asian countries have restricted the use of kratom due to the potential for abuse.
The fact that kratom is derived from a plant should not lead consumers to be believe it 100 percent safe and "all-natural". While certainly not all botanicals have dangerous properties, drugs with dangerous effects can come from botanicals, for example, heroin (opium poppy), cocaine (coca leaves), and nicotine (tobacco).
Will a Drug Test Identify Kratom Use?
-------------------------------------
Currently, kratom is not included in standard drug screens in the US. Kratom tests are available for screening but are not widely available.
Conclusion
----------
Kratom, an herbal product that originated in Southeast Asia, is being used in the US to ease anxiety, treat chronic pain and to reverse opioid withdrawal symptoms; often purchased over the Internet. Recreational use may be on the rise, too. Use in coffee shops has been reported.
The primary psychoactive component, mitragynine, is many times more potent than morphine. DEA lists kratom as a drug and chemical of concern, and is in the process of evaluating kratom for placement into controlled substances scheduling.
Placing kratom into schedule I would place it in the same category as heroin, LSD or marijuana, and prevent access for medical research, a concern for many experts, consumers, and advocacy groups. Lack of quality scientific evidence confounds the evaluation of the safety of kratom. Concerns also exist that the general public would not be able to identify or confirm the quality or purity of kratom from any Internet source.
The FDA has warned consumers not to use any products labeled as containing kratom. As of February 2018, the FDA has reported on 44 related deaths linked with kratom use, often in use with other substances.
Health care professionals and consumers should report any adverse events related to products containing kratom to the FDA's MedWatch program."
and now salmonellosis. - Mod.LL
HealthMap/ProMED-mail map:
United States: http://healthmap.org/promed/p/106]
****************************************************
A ProMED-mail post
http://www.promedmail.org
ProMED-mail is a program of the
International Society for Infectious Diseases
http://www.isid.org
Date: Tue 20 Feb 2018, 10:30 AM ET
Source: CDC [edited]
https://www.cdc.gov/salmonella/kratom-02-18/index.html
Multistate Outbreak of _Salmonella_ I 4,[5],12:b:- Infections Linked to Kratom
--------------------------------------------------------------------------------
CDC, public health and regulatory officials in several states, and the FDA are investigating a multistate outbreak of _Salmonella [enterica_ serotype] I 4,[5],12:b:- infections.
Public health investigators are using the PulseNet system to identify illnesses that may be part of this outbreak. PulseNet is the national subtyping network of public health and food regulatory agency laboratories coordinated by CDC. DNA fingerprinting is performed on _Salmonella_ bacteria isolated from ill people by using techniques called pulsed-field gel electrophoresis (PFGE) and whole genome sequencing (WGS). CDC PulseNet manages a national database of these DNA fingerprints to identify possible outbreaks. WGS gives a more detailed DNA fingerprint than PFGE.
As of [16 Feb 2018], 28 people infected with the outbreak strain of _S._ I 4,[5],12:b:- have been reported from 20 states. A list of the states and the number of cases in each can be found on the Case Count Map page. WGS performed on isolates from ill people were closely related genetically. This means that people in this outbreak are more likely to share a common source of infection.
States / Case Count
Alabama / 1
Arizona / 1
California / 3
Colorado / 1
Florida / 1
Kansas / 1
Kentucky / 1
Louisiana / 1
Massachusetts / 1
Michigan / 1
North Carolina / 2
North Dakota / 1
New York / 1
Ohio / 2
Oklahoma / 2
Oregon / 2
Pennsylvania / 2
South Carolina / 1
Tennessee / 1
Utah / 2
Total / 28
Illnesses started on dates ranging from [13 Oct 2017] to [30 Jan 2018]. Ill people range in age from 6 to 67 years, with a median age of 41. 16 people are male. A total of 11 hospitalizations have been reported. No deaths have been reported.
WGS analysis did not identify any predicted antimicrobial resistance in isolates from 5 ill people. Testing of outbreak isolates using standard antimicrobial susceptibility testing methods is currently underway in CDC's National Antimicrobial Resistance Monitoring System (NARMS) laboratory.
Investigation of the Outbreak
-----------------------------
Epidemiologic evidence indicates that kratom is a likely source of this multistate outbreak. Kratom is a plant consumed for its stimulant effects and as an opioid substitute. Kratom is also known as Thang, Kakuam, Thom, Ketom, and Biak.
In interviews, ill people answered questions about the foods they ate and other exposures in the months before they became ill. As many as 8 (73 percent) of 11 people interviewed reported consuming kratom in pills, powder, or tea. No common brands or suppliers of kratom have been identified at this time.
At this time, CDC recommends that people not consume kratom in any form. The investigation indicates that kratom products could be contaminated with _Salmonella_ and could make people sick. CDC's recommendation may change as more information becomes available. This investigation is ongoing and we will provide updates as needed.
--
Communicated by:
ProMED-mail
<promed@promedmail.org>
[The following about kratom is from Drugs.com (https://www.drugs.com/illicit/kratom.html)
Kratom
------
[Author: L. Anderson, PharmD]
Common or Street Names: Thang, Krypton, Kakuam, Thom, Ketum, Biak-Biak (common name in Thailand)
"What is Kratom?
---------------
Kratom (_Mitragyna speciosa_) is a tropical evergreen tree from Southeast Asia and is native to Thailand, Malaysia, Indonesia and Papua New Guinea. Kratom, the original name used in Thailand, is a member of the Rubiaceae family. Other members of the Rubiaceae family include coffee and gardenia. The leaves of kratom are consumed either by chewing, or by drying and smoking, putting into capsules, tablets or extract, or by boiling into a tea. The effects are unique in that stimulation occurs at low doses and opioid-like depressant and euphoric effects occur at higher doses. Common uses include treatment of pain, to help prevent withdrawal from opiates (such as prescription narcotics or heroin), and for mild stimulation. Traditionally, kratom leaves have been used by Thai and Malaysian natives and workers for centuries. The stimulant effect was used by workers in Southeast Asia to increase energy, stamina, and limit fatigue. However, some Southeast Asian countries now outlaw its use.
In the USA, this herbal product has been used as an alternative agent for muscle pain relief, diarrhea, and as a treatment for opiate addiction and withdrawal. However, its safety and effectiveness for these conditions has not been clinically determined, and the FDA has raised serious concerns about toxicity and possible death with use of kratom. As published on 6 Feb 2018, the FDA notes it has no scientific data that would support the use of kratom for medical purposes. In addition, the FDA states that kratom should not be used as an alternative to prescription opioids, even if using it for opioid withdrawal symptoms. As noted by the FDA, effective, FDA-approved prescription medications, including buprenorphine, methadone, and naltrexone, are available from a health care provider, to be used in conjunction with counseling, for opioid withdrawal. Also, they state there are also safer, non-opioid options for the treatment of pain.
DEA Scheduling of Kratom
------------------------
Kratom was on the DEA's list of drugs and chemicals of concern for several years. On 31 Aug 2016, the DEA published a notice that it was planning to place kratom in Schedule I, the most restrictive classification of the Controlled Substances Act. Its 2 primary active ingredients, mitragynine and 7-hydroxymitragynine (7-HMG), would be temporarily placed onto Schedule I on 30 Sep 2016, according to a filing by the DEA. The DEA reasoning was "to avoid an imminent hazard to public safety. The DEA did not solicit public comments on this federal rule, as is normally done.
However, the scheduling of kratom did not occur on 30 Sep 2016. Dozens of members of Congress, as well as researchers and kratom advocates have expressed an outcry over the scheduling of kratom and the lack of public commenting. The DEA withheld scheduling at that time and opened the docket for public comments. Over 23 000 public comments were collected before the closing date of 1 Dec 2016, according to the American Kratom Association. The American Kratom Association is a lobbying and advocacy group in support of kratom use. The American Kratom Association reports that there are a "number of misconceptions, misunderstandings and lies floating around about Kratom."
As reported by the Washington Post in December 2016, Jack Henningfield, an addiction specialist from Johns Hopkins University and Vice President, Research, Health Policy, and Abuse Liability at Pinney Associates, was contracted by the American Kratom Association to research the kratom's effects. In Henningfield's 127 page report he suggested that kratom should be regulated as a natural supplement, such as St. Johns Wort or Valerian, under the FDA's Food, Drug and Cosmetic Act. The American Kratom Association then submitted this report to the DEA during the public comment period.
Next steps include review by the DEA of the public comments in the kratom docket, review of recommendations from the FDA on scheduling, and determination of additional analysis. Possible outcomes could include emergency scheduling and immediate placement of kratom into the most restrictive Schedule I; routine DEA scheduling in schedule 2 through 5 with more public commenting; or no scheduling at all. The timing for the determination of any of these events is unknown.
State laws have banned kratom use in several states including, Indiana, Tennessee, Wisconsin, Vermont, Arkansas, Alabama and the District of Columbia. These states classify kratom as a schedule I substance. Kratom is also noted as being banned in Sarasota County, Florida, San Diego County, California, and Denver, Colorado. The FDA's analysis from February 2018 included 44 reported deaths associated with the use of kratom. According to Governing.com, legislation was considered last year [2017] in at least 6 other states -- Florida, Kentucky, New Hampshire, New Jersey, New York and North Carolina.
What is the Pharmacology of Kratom?
-----------------------------------
As reported in February 2018, the FDA has confirmed from analysis that kratom has opioid properties. More than 20 alkaloids in kratom have been identified in the laboratory, including those responsible for the majority of the pain-relieving action, the indole alkaloid mitragynine, structurally related to yohimbine. Mitragynine is classified as a kappa-opioid receptor agonist and is roughly 13 times more potent than morphine. Mitragynine is thought to be responsible for the opioid-like effects.
Kratom, due to its opioid-like action, has been used for treatment of pain and opioid withdrawal. Animal studies suggest that the primary mitragynine pharmacologic action occurs at the mu and delta-opioid receptors, as well as serotonergic and noradrenergic pathways in the spinal cord. Stimulation at post-synaptic alpha-2 adrenergic receptors, and receptor blocking at 5-hydroxytryptamine 2A may also occur. The 7-hydroxymitragynine may have a higher affinity for the opioid receptors. Partial agonist activity may be involved. Additional animals' studies show that these opioid-receptor effects are reversible with the opioid antagonist naloxone.
Time to peak concentration in animal studies is reported to be 1.26 hours, and elimination half-life is 3.85 hours. Effects are dose-dependent and occur rapidly, reportedly beginning within 10 minutes after consumption and lasting from 1 to 5 hours.
Kratom Effects and Actions
--------------------------
Most of the psychoactive effects of kratom have evolved from anecdotal and case reports. Kratom has an unusual action of producing both stimulant effects at lower doses and more CNS depressant side effects at higher doses. Stimulant effects manifest as increased alertness, boosted physical energy, talkativeness, and a more social behavior. At higher doses, the opioid and CNS depressant effects predominate, but effects can be variable and unpredictable. Consumers who use kratom anecdotally report lessened anxiety and stress, lessened fatigue, pain relief, sharpened focus, relief of withdrawal symptoms,
Beside pain, other anecdotal uses include as an anti-inflammatory, antipyretic (to lower fever), antitussive (cough suppressant), antihypertensive (to lower blood pressure), as a local anesthetic, to lower blood sugar, and as an antidiarrheal. It has also been promoted to enhance sexual function. None of the uses have been studied clinically or are proven to be safe or effective. In addition, it has been reported that opioid-addicted individuals use kratom to help avoid narcotic-like withdrawal side effects when other opioids are not available. Kratom withdrawal side effects may include irritability, anxiety, craving, yawning, runny nose, stomach cramps, sweating and diarrhea; all similar to opioid withdrawal.
Deaths reported by the FDA have involved one person who had no historical or toxicologic evidence of opioid use, except for kratom. In addition, reports suggest kratom may be used in combination with other drugs that have action in the brain, including illicit drugs, prescription opioids, benzodiazepines and over-the-counter medications, like the anti-diarrheal medicine, loperamide (Imodium AD). Mixing kratom, other opioids, and other types of medication can be dangerous. Kratom has been shown to have opioid receptor activity, and mixing prescription opioids, or even over-the-counter medications such as loperamide, with kratom may lead to serious side effects.
Extent of Kratom Use
--------------------
On the Internet, kratom is marketed in a variety of forms: raw leaf, powder, gum, dried in capsules, pressed into tablets, and as a concentrated extract. In the US and Europe, it appears its use is expanding, and recent reports note increasing use by the college-aged population.
The DEA states that drug abuse surveys have not monitored kratom use or abuse in the US, so it's true demographic extent of use, abuse, addiction, or toxicity is not known. However, as reported by the DEA in 2016, there were 660 calls to U.S. poison centers related to kratom exposure from 2010 to 2015.
Kratom Side Effects and Health Hazards
--------------------------------------
Expected opioid-like side effects that may occur with kratom include:
- Sedation
- Nausea
- Sweating
- Dry mouth
- Increased urination
- Loss of appetite
- Itching
- Constipation
- Dizziness
- Confusion
Case reports describe the following adverse effects from kratom: addiction, withdrawal, hypothyroidism, and liver injury, aching of muscles and bones and jerky limb movements.
Kratom addiction and chronic use has led to cases of psychosis with hallucinations, delusion, and confusion. High-dose use may lead to fast heart rate (tachycardia) and low blood pressure (hypotension). Tremor, anorexia and weight loss are other possible side effects with long-term use.
Seizures have been reported when kratom was combined with modafinil in at least one case report. The DEA has also reported seizure adverse events with recreations kratom use.
A case series from Kronstad, et al. described a fatal drug interaction with kratom. A substance, dubbed "Krypton" - a mixture of mitragynine and a metabolite of tramadol - was found post-mortem in 9 people in Sweden over a one year period. Tramadol, an opioid-like prescription pain drug, was most likely added to kratom to boost its narcotic-like effect.
In November 2017 and February 2018, the FDA issued a public health advisory about deadly risks associated with kratom. There have been 44 reports of Kratom-related deaths, sometimes used in combination with other illicit drugs, prescription drugs, or over-the-counter agents such as loperamide (Imodium).
As with many herbal alternatives, designer drugs, or illicit products sold on the Internet, the possibility exists that kratom may also be contaminated with illegal drugs, black market prescription medications, or even poisonous products. Consumers should avoid buying unknown drug products from the Internet. When combined with other drugs -- recreational, prescription, or alcohol -- the effects of kratom are unknown and may be dangerous.
Is Kratom Addictive?
--------------------
Kratom is well-known to be addictive, as found with traditional use by natives over many years in Southeast Asian countries. Withdrawal effects similar to narcotic withdrawal and drug-seeking behaviors have been described in users in Southeast Asia. Many Southeast Asian countries have restricted the use of kratom due to the potential for abuse.
The fact that kratom is derived from a plant should not lead consumers to be believe it 100 percent safe and "all-natural". While certainly not all botanicals have dangerous properties, drugs with dangerous effects can come from botanicals, for example, heroin (opium poppy), cocaine (coca leaves), and nicotine (tobacco).
Will a Drug Test Identify Kratom Use?
-------------------------------------
Currently, kratom is not included in standard drug screens in the US. Kratom tests are available for screening but are not widely available.
Conclusion
----------
Kratom, an herbal product that originated in Southeast Asia, is being used in the US to ease anxiety, treat chronic pain and to reverse opioid withdrawal symptoms; often purchased over the Internet. Recreational use may be on the rise, too. Use in coffee shops has been reported.
The primary psychoactive component, mitragynine, is many times more potent than morphine. DEA lists kratom as a drug and chemical of concern, and is in the process of evaluating kratom for placement into controlled substances scheduling.
Placing kratom into schedule I would place it in the same category as heroin, LSD or marijuana, and prevent access for medical research, a concern for many experts, consumers, and advocacy groups. Lack of quality scientific evidence confounds the evaluation of the safety of kratom. Concerns also exist that the general public would not be able to identify or confirm the quality or purity of kratom from any Internet source.
The FDA has warned consumers not to use any products labeled as containing kratom. As of February 2018, the FDA has reported on 44 related deaths linked with kratom use, often in use with other substances.
Health care professionals and consumers should report any adverse events related to products containing kratom to the FDA's MedWatch program."
and now salmonellosis. - Mod.LL
HealthMap/ProMED-mail map:
United States: http://healthmap.org/promed/p/106]
See Also
Salmonellosis, st Typhimurium - USA: (IA, MN) chicken salad, alert, recall 20180218.5635548Salmonellosis, st I 4,[5,12:b:- and Newport - USA (02): frozen coconut, recall 20180217.5633342
Salmonellosis - USA (03): (IA) chicken salad, alert, recall 20180214.5628958
Salmonellosis - USA (02): (CO) restaurant, fatal 20180212.5622263
Salmonellosis, st Reading - USA: (MN) children, raw pet food, alert, recall 20180211.5620484
Salmonellosis, st Montevideo - USA: restaurant chain, sprouts 20180121.5574088
Salmonellosis, st I 4,[5,12:b:- and Newport - USA: frozen coconut, alert, recall 20180117.5565073
Salmonellosis - USA : frozen coconut, alert, recall 20180110.5550279
2017
----
Salmonellosis - USA (16): (GA) turkey source 20171208.5490043
Salmonellosis, st Newport - USA: (WA, OR) precut melon 20171202.5479308
Foodborne illness - USA (08): (GA) salmonella susp 20171122.5459753
Foodborne illness - USA (07): (MD) oyster festival, RFI 20171112.5439742
Salmonellosis, st. Agbeni - USA (02): pet turtles 20171118.5452185
Salmonellosis, st Heidelberg - USA (02): MDR, cattle contact, RFI 20171117.5450807
Salmonellosis - USA (15): raw tuna, alert, recall 20171027.5408123
Foodborne illness - USA (06): (VA) food festival, Salmonella Javiana 20171025.5401877
Salmonellosis - USA (14): (LA) jambalaya, 2nd pathogen Clostridium perfringens 20171024.5401550
Salmonellosis - USA (13): (LA) jambalaya, 2nd pathogen Clostridium perfringens 20171021.5395792
and other items in the archives
.................................................ll/ao/jh
No hay comentarios:
Publicar un comentario